Medical manufacturer opens North Charleston facility, bringing job opportunities
NORTH CHARLESTON, S.C. (WCBD)—A medical manufacturing company has opened a new facility in North Charleston to build autoinjectors.
Swiss-based SHL Medical recently inaugurated a new 360,000-square-foot facility that features medical device injection molding technology and fully automated assembly capabilities.
According to the company, the $220 million investment has already brought 300 local jobs to the area and is expected to continue creating employment opportunities. A release from 2024 announcing the build said that once the facility is open, an additional 165 jobs will be opened.
SHL Medical built the facility to help meet the growing demand for its product in North America. The autoinjectors will be used for medications for endocrine and metabolic disorders, dermatology, musculoskeletal diseases, and therapy areas.
The facility, just off Palmetto Commerce Parkway on Trade Center Court, is the first autoinjector production site the company has opened in the United States.
'The most trusted autoinjector brand is now made in the USA. We are proud to be contributing to the growth of the local economy and becoming a key player in the area while contributing to our sustainability goals,' adds Kimberlee Steele, Managing Director of North America at SHL Medical.
Several leaders, including North Charleston Mayor Reggie Burgess and South Carolina Gov. Henry McMaster, attended the grand opening.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Hundreds of CDC employees reinstated after being laid off
The Brief Over 460 CDC employees have been reinstated after April layoffs, mainly from public health divisions. Thousands of jobs remain unfilled, with no word on further reinstatements. RFK Jr. appointed eight new vaccine advisers, including controversial figure Dr. Robert Malone. ATLANTA - More than 460 employees at the Centers for Disease Control and Prevention (CDC) have been reinstated after being laid off earlier this year, the U.S. Department of Health and Human Services (HHS) confirmed Wednesday, according to the Associated Press. What we know The employees are among the approximately 2,400 CDC staffers let go in April, a move that sparked widespread backlash and legal challenges. According to HHS, the reinstated workers include 200 employees from the Center for HIV, Hepatitis, STD and Tuberculosis Prevention and another 150 from the Environmental Health division, which includes a lab focused on lead poisoning prevention. PREVIOUS STORIES Reactions to mass layoffs underway at Atlanta-based CDC 2,400 CDC jobs to be cut in HHS overhaul announced by Secretary Kennedy CDC to lose nearly 1,300 probationary employees under Trump's job cuts Former employees and public health advocates have criticized the layoffs for leaving vital public health positions vacant. Reese Williams, a former CDC worker, said the terminations affected key personnel. "They fired a lot of our scientists, a lot of our public health communicators, a lot of anybody to do with DEI, birth defects, anything to do with smoke and health, domestic abuse and domestic violence," Williams said. Williams says the 2,400 roles that were eliminated this year played a critical role in public health. "They took a part a lot of the funding for our global partners. Funding that goes for Ebola or for these diseases that don't necessarily effect us, but could effect us, they took away a lot of that," she said. This is the second wave of reinstatements. In February, about 180 employees who were laid off were later asked to return. Despite the new round of rehirings, thousands of jobs remain unfilled, and officials have not indicated if additional reinstatements are forthcoming. Employees say many vital positions are still left empty. "Eventually, we will all feel this. Even the ones who think they won't feel it. We're going to feel it," Reese said. Meanwhile, HHS Secretary Robert F. Kennedy Jr. has appointed eight new members to the federal vaccine advisory committee. The move follows his abrupt dismissal of the previous panel earlier this week. Among the new appointees is Dr. Robert Malone, a controversial figure known for spreading misinformation about COVID-19 and vaccines. RELATED STORIES RFK Jr.'s newest CDC vaccine panel includes critics of COVID shots, lockdowns Protest against CDC vaccine committee firings held at Atlanta headquarters RFK Jr. ousts entire CDC vaccine panel The committee advises the CDC director on how approved vaccines should be used nationwide.
Business Wire
36 minutes ago
- Business Wire
athenahealth, Humana, and Your Health Closing Critical Gaps at the Point of Care While Reducing Administrative Burden on Clinicians
BOSTON--(BUSINESS WIRE)--athenahealth, a leading provider of network-enabled software and services for healthcare practices nationwide, in collaboration with key partners Humana (NYSE: HUM) and Your Health, a South Carolina-based primary care practice, have received a 2025 Points of Light Award from KLAS. This recognition is for the case study, ' Closing Care Gaps & Reducing the Administrative Burden Through Improved Data Sharing.' This recognition highlights how integrating timely and relevant information directly into the clinical workflow can help improve health outcomes for patients. "Facilitating collaboration between payer and provider organizations to improve care and eliminate administrative tasks is how we can deliver care experience that patients expect and deserve,' said Sam Lambson, VP of Product Management, Data and Ecosystem. 'At Your Health, our clinicians focus on delivering care that's preventative, personalized, and high-quality. This requires our staff to track patients and their health beyond the clinic and identify and address care gaps before they escalate to more serious or costly conditions,' said Will Stillinger, chief operating officer, Your Health. 'Humana and athenahealth have established an open and seamless information exchange that helps us deliver better care while eliminating administrative burden and costly interventions. We are excited by the opportunity for future care intervention pathways based on factors like Social Determinants of Health.' To accomplish this real-time data exchange, Humana and athenahealth partnered to implement athenaPayer's Care and Diagnosis Gaps solutions to identify and surface care and diagnosis gaps among Humana's Medicare Advantage members. Utilizing athenahealth's cloud-based, single instance platform, Your Health clinicians can now see relevant patient information ahead of visits, address identified gaps during the visit, and document diagnoses and care plans directly within athenaOne. Leveraging Da Vinci APIs, athenahealth automatically sends validated data back to Humana to appropriately document and report on the quality of care they provide to members. As the case study reports, athenahealth has uncovered an average of 4.8 additional care gaps and 4.7 additional diagnosis gaps per member among Humana's Medicare Advantage population, and Humana has been able to close 35% of its CMS Star gaps. Your Health clinicians now spend less time identifying care gaps with limited information, improving care while reducing documentation time. 'By investing in improving preventive care and management of chronic conditions, we're able to help our members stay healthier and out of the hospital. And that leads to lower costs for members themselves,' said Chris Walker, associate vice president of Enterprise Transformation and Interoperability, Humana. 'This partnership – and the positive results we've collectively achieved – is another example of how we are working together to improve patient care and deliver better health outcomes.' athenahealth continues to expand its work with payer organizations, boosting information sharing across its network of more than 160,000 providers and facilitating new pathways to improve patient outcomes. To date, athenahealth has surfaced information on more than 25 million care and diagnosis gaps across commercial, Medicare, Medicaid, and ACA lines of business. The company has additional solutions that support provider and payer collaboration, including electronic prior authorization, transition of care, and referral management capabilities. 'We are working to create a thriving healthcare ecosystem that delivers accessible, high-quality, and sustainable care for all,' said Sam Lambson, vice president of Product Management, Data and Ecosystem Platform for athenahealth. 'Our work with Humana and Your Health is an example of exactly what that ecosystem can look like when practices are equipped with purpose-built, innovative solutions that ease clinician burden and enhance patient outcomes. Facilitating collaboration between payer and provider organizations to improve care and eliminate administrative tasks is how we can deliver care experience that patients expect and deserve.' The KLAS Points of Light annual awards celebrate success stories achieved by payers, healthcare organizations, and healthcare IT companies who have partnered to reduce costs and inefficiencies and improve patient experience. The organizations are honored by the recognition and recently presented about their collaboration at the KLAS K2 Collaborative Summit, May 20-22 in Salt Lake City, UT. To learn more about the challenges, outcomes, and key lessons from this collaboration, please visit: About athenahealth, Inc. athenahealth strives to cure complexity and simplify the practice of healthcare. Our innovative technology includes electronic health records, revenue cycle management, and patient engagement solutions that help healthcare providers, administrators, and practices eliminate friction for patients while getting paid efficiently. athenahealth partners with practices with purpose-built software backed by expertise to produce the insights needed to drive better clinical and financial outcomes. We're inspired by our vision to create a thriving ecosystem that delivers accessible, high-quality, and sustainable healthcare for all. Learn more at About Humana Humana Inc. is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at and at About Your Health Your Health is a leading healthcare organization and physician group committed to providing high-quality, patient-centered care across various specialties, including primary and specialty care for seniors in South Carolina, Georgia, and Florida. With 300 physicians, we deliver care in homes, local offices, facilities, and virtually, ensuring services are available wherever needed. Through continuous education and clinical excellence, Your Health aims to improve health outcomes and enhance community well-being. Our team collaborates closely with families and partners to provide coordinated, compassionate care that prioritizes patients. For more information, please visit
Business Wire
36 minutes ago
- Business Wire
Debiopharm and Alkyon Therapeutics Announce Research Collaboration to Advance the Next Generation of Radioligand Therapies
MARTIGNY, Switzerland & LAUSANNE, Switzerland & SAN DIEGO--(BUSINESS WIRE)--Debiopharm ( a privately-owned Swiss biopharmaceutical company committed to establishing tomorrow's standard of care to cure cancer and infectious diseases and Alkyon Therapeutics, Inc., a biotechnology company pioneering precision-targeted therapies, today announced the signing of a co-research agreement to evaluate the feasibility of developing targeted radioligand therapies (RLTs) using Debiopharm's proprietary AbYlink™ conjugation technology for Alkyon's modular antibody platform directed against undisclosed tumor-associated antigens. This collaboration marks a promising step toward a new generation of RLTs designed to deliver potent radiation targeted directly to cancer cells while minimizing damage to healthy tissues. By leveraging the unique strengths of both platforms, the goal is to create more effective, better-tolerated cancer treatments that improve patient quality of life and expand therapeutic options for difficult-to-treat tumors. AbYLink™ technology enables regio-selective lysine conjugation, ensuring the radioligand avoids the target binding site and facilitating streamlined, consistent manufacturing. 'We're intrigued to explore the potential of applying AbYlink™ conjugation technology to the radio-oncology field,' expressed Frederic Levy, Chief Scientific Officer, Debiopharm. 'Leveraging our innovative conjugation platform with Alkyon's engineered antibody scaffolds could open new possibilities for next-generation radiopharmaceuticals with enhanced precision and therapeutic impact.' 'This collaboration reflects our shared commitment to expanding the potential of radioligand therapies,' said Benjamin Titz, Co-Founder and CEO of Alkyon Therapeutics. 'By applying AbYlink™ to our specialized antibody scaffolds and targeting strategies tailored to the unique architecture of solid tumors, we aim to unlock new therapeutic possibilities and advance care for patients with difficult-to-treat solid tumors.' About AbYlink™ AbYlink™ is a versatile and rapid regio-selective chemical conjugation technology for use in preparing diagnostic or therapeutic conjugates. This one-step method results in stable conjugation at defined and invariable sites on the Fc domain of an antibody or the like, with no impact on antigen-binding regions. It enables a seamless and reproducible conjugation of payloads (e.g., a chelator for radiolabeling, a fluorescent dye or a drug) to antibodies or ADCs. The universal applicability of the technology has been demonstrated for various antibody isotypes and payloads. About Alkyon Therapeutics, Inc. Alkyon Therapeutics, Inc. (AlkyonTx™) is a biotechnology company developing next-generation radioligand therapies (RLTs) for solid tumors. By combining precision-engineered antibodies with advanced radiochemistry and dosimetry technologies, Alkyon aims to overcome barriers such as immune exclusion and drug resistance in difficult-to-treat cancers. Its modular platform supports monotherapies, bispecifics, and rational combinations designed to enable differentiated clinical benefit and scalable product development. Debiopharm's commitment to patients Debiopharm aims to develop innovative therapies that target high unmet medical needs primarily in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then hand stewardship to large pharmaceutical commercialization partners to maximize patient access globally. For more information, please visit
